Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

Click for more information

0.00%

8.0¢ kazia therapeutics limited

Memorial Sloan Results Imminent, page-14

First 14 Last

Share
Profile

Follow
Rich&Poor

1,165 Posts.

862

22/07/22

23:34

Post #: 62685360
Share

Originally posted by novogenbuyer: ↑

I'm sure the main reason MSK picked paxalisib for this study is because, unlike alpelisib, paxalisib can actually cross the BBB and can therefore act on brain cancers. Alpelisib can affect head and neck cancers (those outside the brain), but cannot affect cancers within the central nervous system, so alpelisib is useless for brain cancer. If paxalisib can have any effect on brain cancer in this study, it will still be better than alpelisib for this purpose. Of course, the more effective, the better, but there really aren't any standard treatment options yet that I'm aware of.

Expand

novogenbuyer, good post and reasoning.

Further Kazia analysis below, shows paxalisib among most potent PI3K inhibitors.
IMO, expecting positive MSK data results from the study.

Regards.

KZA Price at posting: 55.0¢ Sentiment: Buy Disclosure: Held
10 Upvote

2 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 67 more messages in this thread...

First 14 Last

Add KZA (ASX) to my watchlist